Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
VJOncology avatar; VJ Oncology @VJOncology ·
May 18, 2024 1791839964499415220

🎥@elisabettasabet of @IEOufficiale discusses the Phase III PREcoopERA trial on giredestrant in premenopausal ER+/HER2- #breastcancer:

➡️https://ow.ly/rOye50RJWy9⬅️

@myESMO #ESMOBreast24

Reply on Twitter 1791839964499415220 Retweet on Twitter 1791839964499415220 0 Like on Twitter 1791839964499415220 2 Twitter 1791839964499415220
VJOncology avatar; VJ Oncology @VJOncology ·
May 17, 2024 1791438701412663578

May is #SkinCancerAwarenessMonth 📣

According to The American Cancer Society an estimated 100,640 new #melanomas will be diagnosed in the USA in 2024 🇺🇸

Check out our skin cancer channel for the latest news and updates 👉 https://www.vjoncology.com/subject/skin-cancer

Image for the Tweet beginning: May is #SkinCancerAwarenessMonth 📣 According Twitter feed image.
Reply on Twitter 1791438701412663578 Retweet on Twitter 1791438701412663578 0 Like on Twitter 1791438701412663578 0 Twitter 1791438701412663578
VJOncology avatar; VJ Oncology @VJOncology ·
May 17, 2024 1791410849124360509

📢We’re so excited! Only two weeks to go until #ASCO24!

From May 31st we’ll be interviewing #Oncology experts – to discover the latest in cancer treatment innovations head to ➡️http://VJOncology.com⬅️

@ASCO @VJOncology

Image for the Tweet beginning: 📢We’re so excited! Only two Twitter feed image.
Reply on Twitter 1791410849124360509 Retweet on Twitter 1791410849124360509 1 Like on Twitter 1791410849124360509 1 Twitter 1791410849124360509
VJOncology avatar; VJ Oncology @VJOncology ·
May 17, 2024 1791396796133941327

#ESMOBreast24 | We had the pleasure to speak to @FioriPoulakaki, who discusses QoL issues after axillary treatment in #breastcancer.

Watch out for her interview and our latest podcast episode on our congress highlights at http://VJOncology.com🎙️

@myESMO #bcsm @Oncoalert

Image for the Tweet beginning: #ESMOBreast24 | We had the Twitter feed image.
Reply on Twitter 1791396796133941327 Retweet on Twitter 1791396796133941327 2 Like on Twitter 1791396796133941327 5 Twitter 1791396796133941327
Load More

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos
VJOncology avatar; VJ Oncology @VJOncology ·
May 18, 2024 1791839964499415220

🎥@elisabettasabet of @IEOufficiale discusses the Phase III PREcoopERA trial on giredestrant in premenopausal ER+/HER2- #breastcancer:

➡️https://ow.ly/rOye50RJWy9⬅️

@myESMO #ESMOBreast24

Reply on Twitter 1791839964499415220 Retweet on Twitter 1791839964499415220 0 Like on Twitter 1791839964499415220 2 Twitter 1791839964499415220
VJOncology avatar; VJ Oncology @VJOncology ·
May 17, 2024 1791438701412663578

May is #SkinCancerAwarenessMonth 📣

According to The American Cancer Society an estimated 100,640 new #melanomas will be diagnosed in the USA in 2024 🇺🇸

Check out our skin cancer channel for the latest news and updates 👉 https://www.vjoncology.com/subject/skin-cancer

Image for the Tweet beginning: May is #SkinCancerAwarenessMonth 📣 According Twitter feed image.
Reply on Twitter 1791438701412663578 Retweet on Twitter 1791438701412663578 0 Like on Twitter 1791438701412663578 0 Twitter 1791438701412663578
VJOncology avatar; VJ Oncology @VJOncology ·
May 17, 2024 1791410849124360509

📢We’re so excited! Only two weeks to go until #ASCO24!

From May 31st we’ll be interviewing #Oncology experts – to discover the latest in cancer treatment innovations head to ➡️http://VJOncology.com⬅️

@ASCO @VJOncology

Image for the Tweet beginning: 📢We’re so excited! Only two Twitter feed image.
Reply on Twitter 1791410849124360509 Retweet on Twitter 1791410849124360509 1 Like on Twitter 1791410849124360509 1 Twitter 1791410849124360509
VJOncology avatar; VJ Oncology @VJOncology ·
May 17, 2024 1791396796133941327

#ESMOBreast24 | We had the pleasure to speak to @FioriPoulakaki, who discusses QoL issues after axillary treatment in #breastcancer.

Watch out for her interview and our latest podcast episode on our congress highlights at http://VJOncology.com🎙️

@myESMO #bcsm @Oncoalert

Image for the Tweet beginning: #ESMOBreast24 | We had the Twitter feed image.
Reply on Twitter 1791396796133941327 Retweet on Twitter 1791396796133941327 2 Like on Twitter 1791396796133941327 5 Twitter 1791396796133941327
Load More

Late-Breaking Abstracts at ASCO 2022!

View all
1:28
PARADIGM: panitumumab superior to bevacizumab as 1L treatment of patients with RAS WT mCRC
Takayuki Yoshino • 5 Jun 2022
2:19
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
Robert Jones • 4 Jun 2022
1:22
KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC
Alexander Spira • 3 Jun 2022
5:11
DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC
Hope Rugo • 5 Jun 2022

Latest videos from ASCO 2022

View all
1:13
Promising future of PSMA for prostate cancer
Eugene Shenderov • 10 Jun 2022
6:57
Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
1:42
Next-generation ALK inhibitors: treatment sequencing and resistance
Alessandra Bearz • 6 Jun 2022
1:17
MK-0482-001: evaluating MK-0482 plus pembrolizumab in patients with advanced solid tumors
Andre Goy • 5 Jun 2022

Breast Cancer at ASCO 2022

View all
3:01
Assessing elacestrant in ctDNA-positive patients with ER+ breast cancer
Thomas Meyskens • 30 May 2022
4:29
Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancer
Thomas Meyskens • 30 May 2022
2:35
AMEERA-6: Amcenestrant, a novel SERD, in HR+ breast cancer
Thomas Meyskens • 30 May 2022
1:08
DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancer
Thomas Meyskens • 30 May 2022

GU at ASCO 2022

View all
1:13
Promising future of PSMA for prostate cancer
Eugene Shenderov • 10 Jun 2022
6:57
Phase II trial of enoblituzumab for patients with intermediate/high-risk localised prostate cancer
Eugene Shenderov • 10 Jun 2022
1:59
Next steps for belzutifan for Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 17 Jun 2022
13:17
Belzutifan for Von Hippel-Lindau syndrome
Ramaprasad Srinivasan • 17 Jun 2022
The content of VJOncology is intended for healthcare professionals